{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T23:36:07Z","timestamp":1770075367030,"version":"3.49.0"},"reference-count":27,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CLEP"],"DOI":"10.2147\/clep.s562445","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T11:30:14Z","timestamp":1770031814000},"page":"1-13","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Comparability of Antiresorptive Osteoporosis Treatment Groups Among Treatment-Na\u00efve and Treatment-Experienced Women Ages 55 and Older in the United States"],"prefix":"10.2147","volume":"Volume 18","author":[{"given":"Kathleen","family":"Hurwitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Feinstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Samai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akhila","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8333-7666","authenticated-orcid":true,"given":"Tzu-Chieh","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1572-0564","authenticated-orcid":true,"given":"M Alan","family":"Brookhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,2]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention D, Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785\u2013795. doi:10.1001\/jama.285.6.785.","DOI":"10.1001\/jama.285.6.785"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1097\/GME.0000000000001831","volume":"28","author":"Blake","year":"2021","journal-title":"Menopause"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/pds.5037","volume":"29","author":"McGrath","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/1475-6773.12279","volume":"50","author":"Dusetzina","year":"2015","journal-title":"Health Serv Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s40471-020-00243-4","volume":"7","author":"Shi","year":"2020","journal-title":"Curr Epidemiol Rep"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S2352-4642(20)30100-0","volume":"4","author":"Man","year":"2020","journal-title":"Lancet Child Adolesc Health"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/dom.14203","volume":"23","author":"Sainsbury","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1093\/ije\/dyaa029","volume":"49","author":"Lousdal","year":"2020","journal-title":"Int J Epidemiol"},{"key":"ref10","unstructured":"Understanding the use of negative controls to assess the validity of non-interventional studies of treatment using real-world evidence. Duke Margolis Center for Health Policy. Available from: https:\/\/healthpolicy.duke.edu\/events\/understanding-use-negative-controls-assess-validity-non-interventional-studies-treatment. Accessed January 22, 2025."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"S114","DOI":"10.1097\/MLR.0b013e3181dbebe3","volume":"48","author":"Brookhart","year":"2010","journal-title":"Med Care"},{"key":"ref12","volume-title":"Statistical Models in Epidemiology, the Environment, and Clinical Trials","year":"2000"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/bimj.201800298","volume":"62","author":"Ozenne","year":"2020","journal-title":"Biom J"},{"key":"ref14","first-page":"S361","volume":"29","author":"Breskin","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00001648-199001000-00010","volume":"1","author":"Rothman","year":"1990","journal-title":"Epidemiology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1007\/s12325-016-0360-3","volume":"33","author":"Goldshtein","year":"2016","journal-title":"Adv Ther"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1359\/jbmr.050304","volume":"20","author":"Johnell","year":"2005","journal-title":"J Bone Miner Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/aje\/kwz083","volume":"188","author":"Zhang","year":"2019","journal-title":"Am J Epidemiol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/AJE\/KWU485","volume":"182","author":"McGrath","year":"2015","journal-title":"Am J Epidemiol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(02)08761-5","volume":"359","author":"Kanis","year":"2002","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.sapharm.2005.12.001","volume":"2","author":"Lobo","year":"2006","journal-title":"Res Soc Adm Pharm"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/oxfordjournals.aje.a008895","volume":"144","author":"Blais","year":"1996","journal-title":"Am J Epidemiol"},{"key":"ref23","unstructured":"U.S. Food and Drug Administration. FDA approves first interchangeable biosimilars to Prolia and Xgeva to treat certain types of osteoporosis and prevent bone events in cancer [news release]. U.S. Food and Drug Administration; 2024. Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-first-interchangeable-biosimilars-prolia-and-xgeva-treat-certain-types-osteoporosis-and. Accessed December 9, 2025."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00223-025-01420-7","volume":"16","author":"Heilmeier","year":"2025","journal-title":"Calcif Tissue Int"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/ajg.2011.113","volume":"106","author":"Ngamruengphong","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3390\/JCM10051140","volume":"10","author":"Hayes","year":"2021","journal-title":"J Clin Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/J.AMJMED.2006.03.029","volume":"120","author":"Brookhart","year":"2007","journal-title":"Am J Med"}],"container-title":["Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/111572","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/111572","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T11:30:15Z","timestamp":1770031815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/real-world-comparability-of-antiresorptive-osteoporosis-treatment-grou-peer-reviewed-fulltext-article-CLEP"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":27,"URL":"https:\/\/doi.org\/10.2147\/clep.s562445","relation":{},"ISSN":["1179-1349"],"issn-type":[{"value":"1179-1349","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}